Erik Berntorp

Summary

Affiliation: Lund University
Country: Sweden

Publications

  1. doi request reprint Identifying non-responsive bleeding episodes in patients with haemophilia and inhibitors: a consensus definition
    E Berntorp
    Malmo University Hospital, Malmo, Sweden University Hospital of Wales, Cardiff, UK
    Haemophilia 17:e202-10. 2011
  2. ncbi request reprint Thrombosis in patients with hemorrhagic disorders
    E Berntorp
    Lund University, Malmö Centre for Thrombosis and Haemostasis, Skåne University Hospital Malmö, Malmo, Sweden
    Minerva Med 104:169-73. 2013
  3. doi request reprint Third Åland islands conference on von Willebrand disease, 26-28 September 2012: meeting report
    E Berntorp
    Department of Hematology and Coagulation Disorders, Lund University, Skane University Hospital, Malmo, Sweden
    Haemophilia 19:1-18. 2013
  4. doi request reprint Von Willebrand disease
    Erik Berntorp
    Malmö Centre for Thrombosis and Haemostasis, Lund University, Malmo, Sweden
    Pediatr Blood Cancer 60:S34-6. 2013
  5. doi request reprint A prospective registry of European haemophilia B patients receiving nonacog alfa, recombinant human factor IX, for usual use
    E Berntorp
    Malmö Centre for Thrombosis and Haemostasis, Lund University, Skane University Hospital, SE 205 02, Malmo, Sweden
    Haemophilia 18:503-9. 2012
  6. doi request reprint Models of prophylaxis
    Erik Berntorp
    Lund University, Malmö Centre for Thrombosis and Haemostasis, Skane University Hospital, Malmo, Sweden
    Haemophilia 18:136-40. 2012
  7. doi request reprint Treatment of haemophilia A and B and von Willebrand's disease: summary and conclusions of a systematic review as part of a Swedish health-technology assessment
    E Berntorp
    Malmö Centre for Thrombosis and Haemostasis, Skane University Hospital, Lund University, Malmo, Sweden
    Haemophilia 18:158-65. 2012
  8. ncbi request reprint Erik von Willebrand
    Erik Berntorp
    Centre for Thrombosis and Haemostasis, Malmo University Hospital, Malmo, Sweden
    Thromb Res 120:S3-4. 2007
  9. ncbi request reprint Options for treating acute bleeds in addition to bypassing agents: extracorporeal immunoadsorption, FVIII/FIX, desmopressin and antifibrinolytics
    E Berntorp
    Malmö Center for Thrombosis and Hemostasis, Malmo University Hospital, Malmo, Sweden
    Haemophilia 12:62-5; discussion 65-6. 2006
  10. ncbi request reprint Prophylaxis and treatment of bleeding complications in von Willebrand disease type 3
    Erik Berntorp
    Malmö Centre for Thrombosis and Hemostasis, Malmo University Hospital, Malmo, Sweden
    Semin Thromb Hemost 32:621-5. 2006

Collaborators

Detail Information

Publications93

  1. doi request reprint Identifying non-responsive bleeding episodes in patients with haemophilia and inhibitors: a consensus definition
    E Berntorp
    Malmo University Hospital, Malmo, Sweden University Hospital of Wales, Cardiff, UK
    Haemophilia 17:e202-10. 2011
    ..Although it is not intended to replace clinical judgment, this definition can guide the optimal course of treatment for patients with haemophilia and inhibitors...
  2. ncbi request reprint Thrombosis in patients with hemorrhagic disorders
    E Berntorp
    Lund University, Malmö Centre for Thrombosis and Haemostasis, Skåne University Hospital Malmö, Malmo, Sweden
    Minerva Med 104:169-73. 2013
    ..Long-term replacement therapy into old age is becoming more common in hemophilia but will not increase occurrence of thromboembolic disease, as factor levels still will be low and have a preventive effect...
  3. doi request reprint Third Åland islands conference on von Willebrand disease, 26-28 September 2012: meeting report
    E Berntorp
    Department of Hematology and Coagulation Disorders, Lund University, Skane University Hospital, Malmo, Sweden
    Haemophilia 19:1-18. 2013
    ....
  4. doi request reprint Von Willebrand disease
    Erik Berntorp
    Malmö Centre for Thrombosis and Haemostasis, Lund University, Malmo, Sweden
    Pediatr Blood Cancer 60:S34-6. 2013
    ..Findings from the VWD PN studies will hopefully provide more robust evidence for which patients might best benefit from prophylaxis and for appropriate dosing regimens for prophylaxis in patients with VWD...
  5. doi request reprint A prospective registry of European haemophilia B patients receiving nonacog alfa, recombinant human factor IX, for usual use
    E Berntorp
    Malmö Centre for Thrombosis and Haemostasis, Lund University, Skane University Hospital, SE 205 02, Malmo, Sweden
    Haemophilia 18:503-9. 2012
    ..Six patients discontinued because of AEs, primarily related to hypersensitivity. Nonacog alfa was shown to be safe for the treatment of haemophilia B, with a low incidence of serious AEs and ESIs...
  6. doi request reprint Models of prophylaxis
    Erik Berntorp
    Lund University, Malmö Centre for Thrombosis and Haemostasis, Skane University Hospital, Malmo, Sweden
    Haemophilia 18:136-40. 2012
    ..Closer inspection suggests that the primary reasons results differ include different definitions of prophylaxis, clotting factor price, discount rates, choice of outcome measures and time horizon...
  7. doi request reprint Treatment of haemophilia A and B and von Willebrand's disease: summary and conclusions of a systematic review as part of a Swedish health-technology assessment
    E Berntorp
    Malmö Centre for Thrombosis and Haemostasis, Skane University Hospital, Lund University, Malmo, Sweden
    Haemophilia 18:158-65. 2012
    ..The economic consequences of various treatment regimens have been insufficiently analysed. Introduction of national and international registries is important...
  8. ncbi request reprint Erik von Willebrand
    Erik Berntorp
    Centre for Thrombosis and Haemostasis, Malmo University Hospital, Malmo, Sweden
    Thromb Res 120:S3-4. 2007
    ..Today, we know the structure and function of the von Willebrand factor and much of its molecular biology. With the availability of safe and effective products, the treatment of von Willebrand disease is continually improving...
  9. ncbi request reprint Options for treating acute bleeds in addition to bypassing agents: extracorporeal immunoadsorption, FVIII/FIX, desmopressin and antifibrinolytics
    E Berntorp
    Malmö Center for Thrombosis and Hemostasis, Malmo University Hospital, Malmo, Sweden
    Haemophilia 12:62-5; discussion 65-6. 2006
    ..Antifibrinolytics are often administered as an adjunct therapy to the treatment protocol and have also been reported to have a direct anti-inhibitor effect...
  10. ncbi request reprint Prophylaxis and treatment of bleeding complications in von Willebrand disease type 3
    Erik Berntorp
    Malmö Centre for Thrombosis and Hemostasis, Malmo University Hospital, Malmo, Sweden
    Semin Thromb Hemost 32:621-5. 2006
    ..Additional studies are ongoing in an international effort, the von Willebrand Disease Prophylaxis Network...
  11. ncbi request reprint The next generation of hemophilia treatment specialists
    Erik Berntorp
    Malmo University Hospital, Department of Coagulation Disorders, Malmo, Sweden
    Semin Thromb Hemost 32:39-42. 2006
    ..The purpose of these programs is to enhance the clinical expertise and further the professional development of individuals dedicated to treating patients with coagulation disorders...
  12. ncbi request reprint New approaches to using FEIBA in the treatment of inhibitor patients
    Erik Berntorp
    Malmo University Hospital, Malmo, Sweden
    Semin Thromb Hemost 32:22-7. 2006
    ..Hemostasis is difficult to achieve in these patients and new treatment options are being explored. Similarly challenging are refractory bleeds, the management of which is likely to benefit from a systematic treatment approach...
  13. ncbi request reprint The von Willebrand disease prophylaxis network (vWD PN): exploring a treatment concept
    Erik Berntorp
    Department of Coagulation Disorders, Malmo University Hospital, Malmo, Sweden
    Thromb Res 118:S19-22. 2006
    ..The vWD PN aims to further elucidate the role of vWF concentrate prophylaxis in vWD and to identify patients most likely to benefit from prophylaxis...
  14. doi request reprint VWF/FVIII complex and the management of patient with inhibitors: from laboratory to clinical practice
    E Berntorp
    Malmö Centre for Thrombosis and Haemostasis, Malmo University Hospital, Malmo, Sweden
    Haemophilia 13:69-72. 2007
    ..However, the clinical implications of all these findings in vitro need to be established...
  15. doi request reprint Prophylaxis in von Willebrand disease
    E Berntorp
    Malmö Centre for Thrombosis and Haemostasis, Malmo University Hospital, Lund University, Malmo, Sweden
    Haemophilia 14:47-53. 2008
    ..Studies of prophylaxis in VWD are urgently needed to develop evidence-based guidelines for this approach; the VWD International Prophylaxis study, for example, has commenced by the VWD Prophylaxis Network...
  16. doi request reprint Differential response to bypassing agents complicates treatment in patients with haemophilia and inhibitors
    E Berntorp
    Malmo University Hospital, Malmo, Sweden
    Haemophilia 15:3-10. 2009
    ..The objective of this review is to discuss the evidence of a differential haemostatic response to bypassing agents and the potential roles of MOA and patient-specific factors in contributing to the differences in response...
  17. doi request reprint Treatment and prevention of acute bleedings in von Willebrand disease--efficacy and safety of Wilate, a new generation von Willebrand factor/factor VIII concentrate
    E Berntorp
    Malmo University Hospital, Malmö Centre for Thrombosis and Haemostasis, Malmo, Sweden
    Haemophilia 15:122-30. 2009
    ..The large prospective clinical dataset shows that Wilate is efficacious and safe in the treatment and prevention of haemorrhages in all VWD types in both adult and paediatric patients...
  18. doi request reprint Joint outcomes in patients with haemophilia: the importance of adherence to preventive regimens
    E Berntorp
    Centre for Thrombosis and Haemostasis, Malmo University Hospital, Lund University, Lund, Sweden
    Haemophilia 15:1219-27. 2009
    ..By promoting rigorous adherence to prophylactic clotting factor therapies, physicians may be able to help preserve joint function in patients with severe haemophilia...
  19. doi request reprint Haemate P/Humate-P: a systematic review
    Erik Berntorp
    Malmö Centre for Thrombosis and Haemostasis, Malmo University Hospital, Sweden
    Thromb Res 124:S11-4. 2009
    ..Further studies will continue to explore its use in other clinical settings, including as immune tolerance induction therapy for patients with haemophilia A...
  20. doi request reprint Importance of rapid bleeding control in haemophilia complicated by inhibitors
    E Berntorp
    Centre for Thrombosis and Haemostasis, Malmo University Hospital, Lund University, Malmo, Sweden
    Haemophilia 17:11-6. 2011
    ..Consideration of strategies to support rapid control of bleeding--including patient education and awareness, and timely administration of clotting factor--is important...
  21. doi request reprint The role of prophylaxis in bleeding disorders
    E Berntorp
    Malmö Centre for Thrombosis and Haemostasis, Lund University, Skane University Hospital, Malmo, Sweden
    Haemophilia 16:189-93. 2010
    ..These depend on the objective of treatment in the individual patient, which, in turn, is dependent on resources in the health care system...
  22. ncbi request reprint Protecting the joints of mice and men
    E Berntorp
    Malmö Center for Thrombosis and Haemostasis, Malmo University Hospital, Malmo, Sweden
    Haemophilia 14:117-8. 2008
  23. doi request reprint Long-term anti-FVIII antibody response in Bethesda-negative haemophilia A patients receiving continuous replacement therapy
    Jenny Klintman
    Haematology and Coagulation Disorders, Malmo, Sweden
    Br J Haematol 163:385-92. 2013
    ..The results indicate that the immune response to FVIII products within an individual may vary over time. However, the clinical impact of NNA remains unclear. ..
  24. pmc The polygenic nature of inhibitors in hemophilia A: results from the Hemophilia Inhibitor Genetics Study (HIGS) Combined Cohort
    Jan Astermark
    Centre for Thrombosis and Haemostasis, Lund University, Skane University Hospital, Malmo, Sweden
    Blood 121:1446-54. 2013
    ..001. Eight of the 53 were significant predictors among the discordant pairs. Results support the complexity of the immune response and encourage further research with the goal of understanding the pathways involved...
  25. doi request reprint Lifelong prophylaxis in a large cohort of adult patients with severe haemophilia: a beneficial effect on orthopaedic outcome and quality of life
    Mohammed Khawaji
    Malmö Centre for Thrombosis and Haemostasis, Skane University Hospital, Malmö Department of Clinical Sciences, Lund University, Malmo, Sweden
    Eur J Haematol 88:329-35. 2012
    ..In the 1950s, Sweden initiated prophylaxis as a lifelong treatment for haemophilia. It was the first country to do so...
  26. doi request reprint Modern haemophilia care
    Erik Berntorp
    Lund University, Malmö Centre for Thrombosis and Haemostasis, Skane University Hospital, Malmo, Sweden
    Lancet 379:1447-56. 2012
    ..Development of new products with improved pharmacokinetics is the next step to improved therapy...
  27. doi request reprint Combination of FVIII and by-passing agent potentiates in vitro thrombin production in haemophilia A inhibitor plasma
    Jenny Klintman
    Department for Coagulation Disorders, Lund University, Skane University Hospital, Malmo, Sweden
    Br J Haematol 151:381-6. 2010
    ..In conclusion, the amount of thrombin formed in vitro by adding a by-passing agent, was higher in the presence of FVIII. Our findings support the use of FVIII in by-passing therapy to optimize the haemostatic effect...
  28. doi request reprint Cost and outcome: comparisons of two alternative bypassing agents for persons with haemophilia A complicated by an inhibitor
    Katarina Steen Carlsson
    Lund University Centre for Health Economics, LUCHE, Lund, Sweden
    Thromb Haemost 99:1060-7. 2008
    ..The large individual-level variation in reduction of pain supports decisions that consider the individual patient's experience and that accept trade-offs between cost and reduction in pain rather than focusing on cost only...
  29. doi request reprint Increased burden on caregivers of having a child with haemophilia complicated by inhibitors
    Karin Lindvall
    Malmö Centre for Thrombosis and Haemostasis, Skane University Hospital, Lund University, Malmo, Sweden
    Pediatr Blood Cancer 61:706-11. 2014
    ....
  30. doi request reprint A retrospective study of Octaplex in the treatment of bleeding in patients with haemophilia A complicated by inhibitors
    Erik Berntorp
    Centre for Thrombosis and Haemostasis, Skane University Hospital, Lund University, Malmo, Sweden
    Blood Coagul Fibrinolysis 21:577-83. 2010
    ..These results demonstrate that Octaplex overcomes inhibition of FVIII in in-vitro and ex-vivo assays of thrombin generation, and that Octaplex is an effective treatment option for haemophilia A patients with FVIII inhibitors...
  31. ncbi request reprint Polymorphisms in the TNFA gene and the risk of inhibitor development in patients with hemophilia A
    Jan Astermark
    Department for Coagulation Disorders, Malmo University Hospital, SE 205 02 Malmo, Sweden
    Blood 108:3739-45. 2006
    ..Our data imply that the TNFA -308G>A polymorphism within Hap 2 is a useful marker and potential modulator of the immune response to replacement therapy in patients with hemophilia...
  32. ncbi request reprint On-demand vs. prophylactic treatment for severe haemophilia in Norway and Sweden: differences in treatment characteristics and outcome
    K Steen Carlsson
    Department of Community Medicine, Malmo University Hospital, and Lund University Centre for Health Economics, Lund University, Lund, Sweden
    Haemophilia 9:555-66. 2003
    ..Differences were consistently substantial and will affect both costs and benefits of the two treatment strategies...
  33. ncbi request reprint The pharmacokinetics of clotting factor therapy
    E Berntorp
    Department of Coagulation Disorders and Hospital Pharmacy, Malmo University Hospital, Malmo, Sweden
    Haemophilia 9:353-9. 2003
    ..Important applications of clotting factor pharmacokinetics include optimising the treatment and improving its cost-effectiveness during long-term prophylaxis as well as during bleeding episodes and surgery...
  34. ncbi request reprint Antibodies to factor VIIa in patients with haemophilia and high-responding inhibitors
    Jan Astermark
    Department of Coagulation Disorders, University of Lund, University Hospital, Malmo, Sweden
    Br J Haematol 119:342-7. 2002
    ..The characterization of the antibody profile may facilitate an optimal treatment with by-passing agents in severe bleeding events...
  35. ncbi request reprint Polymorphisms in the IL10 but not in the IL1beta and IL4 genes are associated with inhibitor development in patients with hemophilia A
    Jan Astermark
    Department for Coagulation Disorders, Malmo University Hospital, SE 205 02 Malmo, Sweden
    Blood 107:3167-72. 2006
    ..5; P < .001). The association was consistent in the subgroup of families with severe hemophilia and inversions. IL10 is the first gene located outside the causative factor VIII gene mutation to be associated with inhibitor development...
  36. doi request reprint Treatment of the critically ill patient with protein C: is it worth the cost?
    Gunnar Nilsson
    Department of Anaesthesiology and Intensive Care, Lund University, Malmo University Hospital, SE 205 02 Malmo, Sweden
    Thromb Res 125:494-500. 2010
    ..The objectives were to calculate costs of protein C treatment, at best-case scenario, per statistical life saved...
  37. doi request reprint Standardization and clinical utility of thrombin-generation assays
    Erik Berntorp
    Malmö Centre for Thrombosis and Haemostasis, Malmo University Hospital, Malmo, Sweden
    Semin Thromb Hemost 34:670-82. 2008
    ....
  38. doi request reprint Lower incidence of procoagulant abnormalities during follow-up after creation of the Fontan circulation in children
    Olof Rask
    Department of Paediatrics, Malmo University Hospital, Malmo, Sweden
    Cardiol Young 19:152-8. 2009
    ....
  39. ncbi request reprint The APC-PCI complex concentration predicts outcome of aortic surgery
    Gunnar Nilsson
    Department of Anaesthesiology and Intensive Care, Lund University, Malmo University Hospital, SE 205 02 Malmo, Sweden
    Thromb Res 120:237-44. 2007
    ..The purpose of the study was to establish whether the APC-PCI complex can provide information useful for the assessment of outcome after aortic surgery...
  40. ncbi request reprint Regimens of factor VIII administration--continuous infusion vs. bolus
    E Berntorp
    Department of Coagulation Disorders, University of Lund, Malmo University Hospital, Sweden
    Haematologica 85:69-71; discussion 71-2. 2000
    ..However, we conclude that continuous infusion may play a role in immune tolerance induction, and the treatment failures in our study could probably be explained by the fact that the patients were partially selected to be resistant cases...
  41. doi request reprint Anti-prothrombin antibodies are associated with thrombosis in children
    Olof Rask
    Department of Clinical Sciences, Lund University, Malmo University Hospital, Malmo, Sweden
    Thromb Res 125:19-24. 2010
    ..This investigation aimed to evaluate thrombotic risk factors in children, with special reference to autoantibodies against prothrombin and protein S...
  42. ncbi request reprint Long-term prophylaxis in von Willebrand disease
    Erik Berntorp
    Department of Coagulation Disorders, Lund University and Malmö University Hospital, Malmo, Sweden
    Blood Coagul Fibrinolysis 16:S23-6. 2005
    ..More clinical data and controlled trials are needed in order to formulate recommendations for prophylaxis in patients with VWD...
  43. ncbi request reprint A randomized comparison of bypassing agents in hemophilia complicated by an inhibitor: the FEIBA NovoSeven Comparative (FENOC) Study
    Jan Astermark
    Department for Hematology and Coagulation Disorders, Malmö University Hospital SE 205 02 Malmö, Sweden
    Blood 109:546-51. 2007
    ..This trial was registered at www.clinicaltrials.gov as #NCT00166309...
  44. doi request reprint Long-term prophylaxis in severe haemophilia seems to preserve bone mineral density
    M Khawaji
    Department of Medicine, Malmö Centre for Thrombosis and Haemostasis, Malmo University Hospital, Lund University, Malmo Sweden
    Haemophilia 15:261-6. 2009
    ..We did not observe a correlation between BMD and severity of haemophilia. The results indicate that the use of factor prophylaxis since early childhood may preserve normal BMD in severe haemophilia...
  45. ncbi request reprint Immune tolerance induction and the treatment of hemophilia. Malmö protocol update
    E Berntorp
    Department for Coagulation Disorders, University of Lund, Malmo University Hospital, Sweden
    Haematologica 85:48-50; discussion 50-1. 2000
    ..We conclude that the Malmö protocol is efficient for induction of immune tolerance but the patients must be selected particularly with regard to inhibitor duration and time of last booster...
  46. doi request reprint Physical activity for prevention of osteoporosis in patients with severe haemophilia on long-term prophylaxis
    M Khawaji
    Malmö Centre for Thrombosis and Haemostasis, Malmo University Hospital, Malmo, Sweden
    Haemophilia 16:495-501. 2010
    ....
  47. ncbi request reprint In vivo recovery of factor VIII and factor IX: intra- and interindividual variance in a clinical setting
    S Bjorkman
    Hospital Pharmacy, Malmo University Hospital, Malmo, Sweden
    Haemophilia 13:2-8. 2007
    ..However, the findings presented here do not support the assumption that dosing of FVIII or FIX can be individualized on the basis of a clinically determined IVR value...
  48. doi request reprint Thrombin generation in vitro in the presence of by-passing agents in siblings with severe haemophilia A
    J Klintman
    Department for Coagulation Disorders, Malmo University Hospital, Malmo, Sweden
    Haemophilia 16:e210-5. 2010
    ..The nature of these determinants remains to be identified...
  49. ncbi request reprint Impact of inhibitor epitope profile on the neutralizing effect against plasma-derived and recombinant factor VIII concentrates in vitro
    J Astermark
    Department for Coagulation Disorders, University Hospital, Malmo, Sweden
    Haemophilia 9:567-72. 2003
    ..Potential clinical implications of the observed differences in inhibitor reactivity are discussed...
  50. ncbi request reprint A 6-year follow-up of dosing, coagulation factor levels and bleedings in relation to joint status in the prophylactic treatment of haemophilia
    J Ahnström
    Hospital Pharmacy, Malmo University Hospital, Malmo, Sweden
    Haemophilia 10:689-97. 2004
    ..Thus, proposed standard regimens should be implemented only after careful clinical consideration, with a high readiness for re-assessment and individual dose tailoring...
  51. doi request reprint Bone density and health-related quality of life in adult patients with severe haemophilia
    M Khawaji
    Malmö Centre for Thrombosis and Haemostasis, Skane University Hospital, Malmo, Sweden
    Haemophilia 17:304-11. 2011
    ..Reduced BMD in group B correlated with impaired physical health, which underscores the importance of early onset of adequate prophylactic treatment...
  52. doi request reprint Oestrogen treatment of constitutional tall stature in girls: is there a risk of thrombosis or bleeding?
    Olof Rask
    Department of Pediatrics, Centre for Thrombosis and Hemostasis, Malmo University Hospital, Malmo, Sweden
    Acta Paediatr 97:342-7. 2008
    ..To evaluate haemostatic effects and clinical outcome of oestrogen treatment of constitutionally tall stature in girls...
  53. ncbi request reprint A healthy hemophilic patient without arthropathy: from concept to clinical reality
    Erik Berntorp
    Department of Coagulation Disorders, Lund University, Malmo University Hospital, Malmo, Sweden
    Semin Thromb Hemost 29:5-10. 2003
    ..In addition, carrier and prenatal diagnosis add important contributions to improve life for the patient and his family. The next important step for the future is gene therapy, and early clinical studies are already in progress...
  54. ncbi request reprint The Malmö International Brother Study (MIBS): further support for genetic predisposition to inhibitor development in hemophilia patients
    J Astermark
    Department for Coagulation Disorders, University of Lund, Malmo, Sweden
    Haemophilia 7:267-72. 2001
    ..However, the markers of this predisposition remain to be elucidated and we believe that the MIBS registry will be useful for this purpose...
  55. ncbi request reprint Experience with a new percutaneous port system, Percuseal, for intravenous injection in patients with haemophilia, von Willebrand disease and severe alpha1-antitrypsin deficiency
    E Berntorp
    Department for Coagulation Disorders, Lund University, Malmo University Hospital, Malmo, Sweden
    Haemophilia 9:173-8. 2003
    ....
  56. doi request reprint Physical activity and joint function in adults with severe haemophilia on long-term prophylaxis
    Mohamed Khawaji
    Malmö Centre for Thrombosis and Haemostasis, Skane University Hospital, Malmo, Sweden
    Blood Coagul Fibrinolysis 22:50-5. 2011
    ....
  57. doi request reprint Break-through bleeding in relation to predicted factor VIII levels in patients receiving prophylactic treatment for severe hemophilia A
    P W Collins
    Arthur Bloom Haemophilia Centre, Department of Haematology, Medical School of Cardiff University, University Hospital of Wales, Heath Park, Cardiff, UK
    J Thromb Haemost 7:413-20. 2009
    ..Studies to date, however, have not demonstrated a strong link between FVIII level and the bleeding rate...
  58. ncbi request reprint NovoSeven in warfarin-treated patients
    E Berntorp
    Department for Coagulation Disorders, Lund University, University Hospital, Malmo, Sweden
    Blood Coagul Fibrinolysis 11:S113-5. 2000
    ..When rFVIIa was given to a patient with a warfarin-induced nosebleed, it had an immediate haemostatic effect and the International Normalized Ratio value virtually normalized...
  59. ncbi request reprint Pharmacokinetics of recombinant factor IX in relation to age of the patient: implications for dosing in prophylaxis
    S Bjorkman
    Hospital Pharmacy, Malmo University Hospital, Malmo, Sweden
    Haemophilia 7:133-9. 2001
    ..During prophylaxis a 1-U dL(-1) trough level can normally be maintained by dosing every 2-3 days, the former schedule resulting in, on average, a 45% lower consumption of rFIX...
  60. ncbi request reprint Recombinant FVIIa in the treatment of warfarin bleeding
    E Berntorp
    Department for Coagulation Disorders, Lund University, University Hospital, Malmo, Sweden
    Semin Thromb Hemost 26:433-5. 2000
    ..Even if more data are needed before any definite conclusions can be drawn, the outlook so far seems promising...
  61. ncbi request reprint Immune tolerance induction: recombinant vs. human-derived product
    E Berntorp
    Department for Coagulation Disorders, Malmo University Hospital, Malmo, Sweden
    Haemophilia 7:109-13. 2001
    ..Different theoretical aspects indicate that human-derived concentrate, especially of low purity, and with a high content of von Willebrand factor, may have a better tolerizing effect...
  62. ncbi request reprint Prophylactic therapy for haemophilia: early experience
    E Berntorp
    Department of Coagulation Disorders, Malmo University Hospital, Malmo, Sweden
    Haemophilia 9:5-9; discussion 9. 2003
    ..These issues are of great economic importance, and the need for health economical studies is obvious...
  63. ncbi request reprint Pharmacokinetics of coagulation factors: clinical relevance for patients with haemophilia
    S Bjorkman
    Hospital Pharmacy and Department for Coagulation Disorders, Malmo University Hospital, Sweden
    Clin Pharmacokinet 40:815-32. 2001
    ..In conclusion, therapeutic monitoring of coagulation factor levels and the use of clinical pharmacokinetics to aid therapy are well established in the treatment of patients with haemophilia...
  64. ncbi request reprint An approach to study the viral safety of plasma-derived products in previously treated, non-infected patients
    E Berntorp
    Department for Coagulation Disorders, Lund University, University Hospital, Malmo, Sweden
    Haemophilia 7:360-3. 2001
    ....
  65. ncbi request reprint Tailored pharmacokinetic dosing allows self-administration and reduces the cost of IV augmentation therapy with human alpha(1)-antitrypsin
    Eeva Piitulainen
    Department of Respiratory Medicine, Malmo University Hospital, Lund University, 20502, Malmo, Sweden
    Eur J Clin Pharmacol 59:151-6. 2003
    ..The objective of this investigation was to study whether tailored pharmacokinetic dosing of human AAT allows self-administration and reduces the total annual dose and cost of intravenous augmentation therapy...
  66. ncbi request reprint Protein C levels can be forecasted by global haemostatic tests in critically ill patients and predict long-term survival
    Gunnar Nilsson
    Department of Anaesthesiology, Lund University, Malmo University Hospital, SE 205 02 Malmo, Sweden
    Thromb Res 116:15-24. 2005
    ..We therefore studied the usefulness of global haemostatic tests to predict levels of protein C and antithrombin and investigated value of these latter tests in predicting outcome...
  67. ncbi request reprint Risk factors for venous thrombosis in Swedish children and adolescents
    Olof Rask
    Department of Paediatrics, University Hospital, Malmo, Sweden
    Acta Paediatr 94:717-22. 2005
    ..To identify prothrombotic risk profiles in children and adolescents referred to a regional coagulation centre in southern Sweden for a first thrombotic event...
  68. ncbi request reprint Costs of on-demand and prophylactic treatment for severe haemophilia in Norway and Sweden
    K Steen Carlsson
    Department of Community Medicine, Malmö University Hospital and Lund University Centre for Health Economics, Lund University, Lund, Sweden
    Haemophilia 10:515-26. 2004
    ..For on-demand, the annual costs would increase by approximately the same proportion as an increase in the prescribed dose kg(-1)...
  69. ncbi request reprint Inhibitor treatment in haemophilias A and B: summary statement for the 2006 international consensus conference
    E Berntorp
    Department of Coagulation Disorders, Malmo University Hospital, Malmo, Sweden
    Haemophilia 12:1-7. 2006
    ..Finally, conference participants urged their colleagues to participate in the currently ongoing international trials of ITI...
  70. ncbi request reprint Two new candidate mutations in type IIA von Willebrand's disease (Arg834-->Gly, Gly846-->Arg) and one polymorphism (Tyr821-->Cys) in the A2 region of the von Willebrand factor
    M Donner
    Dept of Paediatrics, University Hospital, Lund, Sweden
    Eur J Haematol 51:38-44. 1993
    ..In addition, two sequence variations not linked to the phenotype were found, namely Tyr821-->Cys and Val802-->Leu...
  71. pmc Modern treatment of haemophilia
    E Berntorp
    Department of Coagulation Disorders, Allmanna Sjukhuset, Malmo, Sweden
    Bull World Health Organ 73:691-701. 1995
    ..The present review article summarizes the discussions and recommendations made by the participants...
  72. ncbi request reprint The Malmö-Klaipeda WFH twinning programme: a comparative description of the haemophilia cohorts
    E Berntorp
    Department for Coagulation Disorders, University of Lund, University Hospital, Malmo, Sweden
    Haemophilia 4:79-82. 1998
    ..This should not only form a suitable platform for the future development of haemophilia care in Lithuania, but could also serve as an example for liaisons between other haemophilia centres...
  73. ncbi request reprint Factor V Q506 (resistance to activated protein C) and prognosis after acute coronary syndrome
    J Holm
    Department of Cardiology, University Hospital, Malmo, Sweden
    Thromb Haemost 81:857-60. 1999
    ..Our results demonstrate a gene-environment interaction between smoking and the FV:Q506 allele, with an increased risk of early complications after an acute ischemic event...
  74. ncbi request reprint Second generation, B-domain deleted recombinant factor VIII
    E Berntorp
    Department for Coagulation Disorders, University of Lund, University Hospital, Malmo, Sweden
    Thromb Haemost 78:256-60. 1997
    ..The safety margin regarding human viruses and other protein contaminants should be better with r-VIII SQ than with earlier products, which all contain far more human protein in their formulations...
  75. ncbi request reprint Liposuction in Dercum's disease: impact on haemostatic factors associated with cardiovascular disease and insulin sensitivity
    E Berntorp
    Department of Coagulation Disorders, University of Lund, Malmo University Hospital, Sweden
    J Intern Med 243:197-201. 1998
    ..To study the impact of adipose tissue removal by liposuction on factors associated with increased risk of cardiovascular atherosclerotic disease within the coagulation and fibrinolytic system and glucose metabolism...
  76. ncbi request reprint Economic evaluation: what are we looking for and how do we get there?
    K Steen Carlsson
    Department of Community Medicine, Malmö University Hospital and Lund University Centre for Health Economics, Lund University, Sweden
    Haemophilia 10:44-9. 2004
    ..Accordingly, regardless of the chosen evaluation method, data requirements are non-trivial. Hence, the various problems connected to the generation of data, as well as how they may be addressed, are also discussed...
  77. ncbi request reprint Willingness to pay for on-demand and prophylactic treatment for severe haemophilia in Sweden
    K Steen Carlsson
    Department of Community Medicine, Malmö University Hospital and Lund University Centre for Health Economics, Lund University, Lund, Sweden
    Haemophilia 10:527-41. 2004
    ..The WTP for on-demand and prophylaxis exceeded the calculated cost of treatment per taxpayer of providing on-demand and prophylactic treatment, respectively, based on our previous results...
  78. ncbi request reprint Clinical spectrum of hepatitis C-related liver disease and response to treatment with interferon and ribavirin in haemophilia or von Willebrand disease
    S Lethagen
    Department for Coagulation Disorders, University of Lund, University Hospital, Malmo, Sweden
    Br J Haematol 113:87-93. 2001
    ....
  79. ncbi request reprint Consensus perspectives on prophylactic therapy for haemophilia: summary statement
    E Berntorp
    Department of Coagulation Disorders, Malmo University Hospital, Malmo, Sweden
    Haemophilia 9:1-4. 2003
    ..Such studies should include carefully defined cohorts, validated orthopaedic and quality-of-life assessment instruments, and cost-benefit analyses...
  80. ncbi request reprint Anti- and procoagulant activities in factor VII-deficient subjects
    J Astermark
    Department of Coagulation Disorders, University Hospital, University of Lund, Malmo, Sweden
    Thromb Res 101:435-40. 2001
    ..Whether this could influence the clinical feature, including the risk of thromboembolic events in association with replacement therapy, remains to be evaluated...
  81. ncbi request reprint The prognostic value of global haemostatic tests in the intensive care unit setting
    G Nilsson
    Departments of Anaesthesiology and Coagulation Disorders, Lund University, Malmo University Hospital, Malmo, Sweden
    Acta Anaesthesiol Scand 46:1062-7. 2002
    ..We examined the clinical applicability to predict the outcome of the global haemostatic tests used at most hospitals...
  82. ncbi request reprint Gadolinium contrast agent is of limited value for magnetic resonance imaging assessment of synovial hypertrophy in hemophiliacs
    B Lundin
    Department of Radiology, University Hospital of Lund, Lund, Sweden
    Acta Radiol 48:520-30. 2007
    ....
  83. ncbi request reprint Progress in haemophilic care: ethical issues
    E Berntorp
    Department of Coagulation Disorders, Lund University, Malmo University Hospital, Malmo, Sweden
    Haemophilia 8:435-8. 2002
    ....
  84. ncbi request reprint Von Willebrand: the scientist, the disease, the factor, and the treatment
    Erik Berntorp
    Thromb Res 120:S1. 2007
  85. pmc Delays in maturation among adolescents with hemophilia and a history of inhibitors
    Sharyne M Donfield
    Department of Biostatistics, Rho, Chapel Hill, NC, USA
    Blood 110:3656-61. 2007
    ..The results of this investigation underscore the importance of monitoring the growth and maturation of children and adolescents with hemophilia, particularly those with inhibitors...
  86. ncbi request reprint Limited protective effect of the CCR5Delta32/CCR5Delta32 genotype on human immunodeficiency virus infection incidence in a cohort of patients with hemophilia and selection for genotypic X4 virus
    Astrid K N Iversen
    Department of Medical Microbiology and Immunology, Arhus University School of Medicine, Denmark
    J Infect Dis 187:215-25. 2003
    ..Sequence comparisons indicate that X4 virus can be selected in vivo due to either absence of CCR5 receptors or relative increase of CXCR4 receptors...
  87. ncbi request reprint The need for prophylaxis in von Willebrand's disease and other coagulation disorders
    Alison Street
    Thromb Res 118:S1-2. 2006
  88. ncbi request reprint Variation in factor VIII inhibitor reactivity with different commercial factor VIII preparations: is it of clinical importance?
    Erik Berntorp
    Angelo Bianchi Bonomi Hemophilia Thrombosis Center, Department of Internal Medicine, IRCCS Maggiore Hospital and University of Milan, Italy
    Haematologica 88:EREP03. 2003
    ..Even if formal, well-controlled studies are needed, it can already be recommended that inhibitor plasma should be tested against a panel of concentrates in order to select the less neutralized concentrate for use in inhibitor patients...
  89. ncbi request reprint Cost effectiveness of haemophilia treatment: a cross-national assessment
    Barbara Lippert
    Department of Haemostasis and Transfusion Medicine, University Hospital of Munich, Germany
    Blood Coagul Fibrinolysis 16:477-85. 2005
    ..7 million Euro dollars per quality-adjusted life year. Based on our decision analysis, the use of prophylactic treatment was overall more effective than on-demand therapy in young haemophiliacs, but at extremely high cost...
  90. ncbi request reprint Biologic response to desmopressin in patients with severe type 1 and type 2 von Willebrand disease: results of a multicenter European study
    Augusto B Federici
    Angelo Bianchi Bonomi Hemophilia and Thrombosis Center, Department of Internal Medicine and Dermatology, IRCCS Maggio e Hospital and University of Milan, Italy
    Blood 103:2032-8. 2004
    ..This prospective study showed that the rate of biologic response to DDAVP is relatively low not only in type 2 but also in type 1 VWD when uniform and stringent criteria for patient selection and responsiveness are applied...
  91. ncbi request reprint The Malmö International Brother Study (MIBS). Genetic defects and inhibitor development in siblings with severe hemophilia A
    Jan Astermark
    Department for Coagulation Disorders University Hospital SE 205 02 Malmö, Sweden
    Haematologica 90:924-31. 2005
    ..The objective of this study was to evaluate the mutation type dependent concordance rate of inhibitor formation in siblings...
  92. ncbi request reprint Surgical evaluation of a recombinant factor VIII prepared using a plasma/albumin-free method: efficacy and safety of Advate in previously treated patients
    Claude Negrier
    Hopital Edouard Herriot, Centre Régional de Traitement de l Hémophilie, Pavillon E, Place d Arsonval, Lyon, France
    Thromb Haemost 100:217-23. 2008
    ..In conclusion, rAHF-PFM administered via continuous infusion or bolus injections is safe, non-immunogenic, and effective for perioperative hemostatic management in previously treated haemophilia A patients...